Pergolide (Celance – Lilly) is structurally related to bromocriptine and lysuride. Like them it is a dopamine agonist intended for use with levodopa in Parkinson’s disease,1 but unlike other agonists pergolide stimulates D1 as well as D2 receptors. The manufacturer suggests that this ‘dual action’ allows ‘full expression of the effects of dopaminergic therapy’ and ‘may contribute to the therapeutic efficacy’, but the clinical relevance of differential dopamine receptor stimulation is not known.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.